Diagnosis and Treatment of Mature T-Cell Leukemias Explained
Publication Title: How We Evaluate and Treat Leukemic Presentations of Mature T-Cell Lymphomas
Summary
- Question
- This study reviewed how mature T-cell leukemias, rare cancers originating from mature T-cells, are evaluated and treated. The researchers focused on four major subtypes: T-cell prolymphocytic leukemia (T-PLL), adult T-cell leukemia/lymphoma (ATLL), T-large granular lymphocytic leukemia (T-LGL), and Sézary syndrome (SS). The goal was to outline diagnostic strategies and treatment approaches tailored to these subtypes.
- Why it Matters
- Mature T-cell leukemias are challenging to diagnose and treat due to their rarity and complexity. Misdiagnosis can lead to inappropriate treatments, while delays in diagnosis worsen outcomes. Accurate identification and subtype-specific management are critical, as these cancers differ in aggressiveness, clinical features, and treatment options. Improving diagnostic and therapeutic strategies could enhance patient survival and quality of life, particularly for aggressive subtypes such as T-PLL and ATLL.
- Methods
- The authors summarized diagnostic and therapeutic approaches based on clinical features, laboratory tests, genetic analyses, and subtype-specific markers. For diagnosis, they emphasized distinguishing malignant clonal T-cell proliferations from non-malignant causes using tools such as immunophenotyping, clonality studies, and genetic testing. Treatment strategies varied by subtype, incorporating immunosuppressive therapy, chemotherapy, monoclonal antibodies, and stem cell transplantation.
- Key Findings
- The study highlighted key diagnostic markers for each subtype. For example, T-PLL cells often exhibit genetic abnormalities involving the TCL1 gene, while ATLL requires evidence of infection with the HTLV-1 virus. Treatment efficacy also varies: Alemtuzumab (a monoclonal antibody) is effective in T-PLL, while interferon-alpha and azidothymidine (AZT) are cornerstones for indolent ATLL. In SS, multimodal approaches combining extracorporeal photopheresis, systemic therapy, and monoclonal antibodies such as Mogamulizumab are standard.
- Implications
- This review underscores the importance of subtype-specific diagnostic and treatment protocols. For aggressive subtypes like T-PLL and ATLL, early intervention and stem cell transplantation can improve outcomes. For indolent subtypes such as T-LGL, low-dose immunosuppressive therapy can effectively manage symptoms. Multimodal approaches in SS improve quality of life and extend survival. The findings provide clinicians with structured guidelines to optimize care for these rare leukemias.
- Next Steps
- The authors recommend further research into targeted therapies, such as JAK inhibitors and monoclonal antibodies, which show promise in treating relapsed or refractory cases. They also emphasize the need for collaborative clinical trials to refine treatment strategies and improve long-term outcomes for patients with mature T-cell leukemias.
- Funding Information
- This research received no external funding. Yale University also provided funding and support for this research.
Full Citation
Ravishankar A, Somaya V, Qureshi H, Kiwan A, Montanari F, Girardi M, Foss F, Sethi T. How We Evaluate and Treat Leukemic Presentations of Mature T-Cell Lymphomas. Cancers 2026, 18: 965. PMID: 41899567, PMCID: PMC13024611, DOI: 10.3390/cancers18060965.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.
Authors
Arjun Ravishankar
First AuthorTarsheen Sethi, MD, MSc
Last AuthorAssistant Professor of Medicine (Hematology)
Additional Yale School of Medicine Authors
Other Authors
Research Themes
Concepts
- T large granular lymphocyte leukemia;
- Mature T-cell leukemias;
- Adult T-cell leukemia/lymphoma;
- T-cell prolymphocytic leukemia;
- Non-Hodgkin's lymphoma;
- Leukemic presentation;
- T cells;
- T-cell leukemia;
- Sezary syndrome;
- Clinical features;
- T-cell non-Hodgkin's lymphoma;
- Mature T-cell lymphomas;
- Discussion of clinical features;
- T-cell lymphocytosis;
- T-cell clonality;
- B-cell lymphocytosis;
- T-cell lymphoma;
- T-cell leukemia/lymphoma;
- Granular lymphocytic leukemia;
- Mature T cells;
- Systematic diagnostic approach;
- Approach to diagnosis;
- Prolymphocytic leukemia;
- Lymphocytic leukemia;
- Therapeutic challenge